Creation of a collection of blood samples that will be collected before and then under treatment in patients with digestive adenocarcinoma during the 1st and 2nd metastatic line and which, depending on scientific progress, can be used for research projects aimed at developing tailored patient management strategies.
Male or female ≥ 18 years old
Histological documentation of adenocarcinoma of the colon or rectum, small intestine, pancreas, stomach, bile duct, oesophagus
Patient who will receive a first or second line metastatic chemotherapy and/or targeted therapy
Informed consent form (ICF) signed
Male or female < 18 years old
Non-adenocarcinoma histological type
Patient already undergoing specific treatment (chemotherapy and/or targeted therapy) in 1st or 2nd metastatic line
Pregnant and/or breastfeeding woman
Single group
Biological collection
Other intervention\- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment
Number of clinical risk factors for metastatic digestive cancer
Number of biological risk factors for metastatic digestive cancer
Click on the lead sponsor to view all of their trials.
